In contrast, in vivo models, such as imiquimod (IMQ)-induced psoriasis in mice, demonstrate that IL-17A signaling ablation significantly reduces skin inflammation, allowing direct assessment of disease phenotypes and therapeutic efficacy (e.g., FXYD3 deletion mitigates severity) (80, 84). Here, IL17A is linked to psoriasis.